Phase II study of alternating cytoreductive and cycle-active combination chemotherapy for metastatic breast cancer

C. L. Vogel, N. H. Love, D. R. East, M. R. Moore, R. V. Smalley

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Nineteen females with metastatic breast cancer (73% with visceral disease) treated with cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) cytoreduction followed by, and then alternated with, an extensive 'cycle-active' regimen were evaluable. Sixteen of the 19 (84%) patients responded to CAF prior to initiation of the cycle-active regimen, and median remission duration for CAF responders was 50 weeks. The regimen was tolerable and the remission rates and durations were at least as good as those seen with CAF alone. This regimen is now being compared with CAF in a randomized trial of the Southeastern Cancer Study Group.

Original languageEnglish (US)
Pages (from-to)2077-2079
Number of pages3
JournalCancer Treatment Reports
Volume63
Issue number11-12
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of alternating cytoreductive and cycle-active combination chemotherapy for metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this